CDC updates ACIP charter

FDA advisory panel recommends first-of-its-kind mRNA flu vaccine for older adults

An FDA advisory panel has recommended approval of Moderna’s mRNA-based flu vaccine, mFlusiva, for adults ages 50-64, and adults 65 and older, if a specific condition is met.

June 26, 2026

Vol.52 No.25

By Claire Marie Porter

At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer

If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.

June 05, 2026

Vol.52 No.22

By Sara Willa Ernst, Claire Marie Porter and Paul Goldberg

Cancer Policy

FDA advisory panel votes to recommend updated 2026-2027 formula for COVID-19 vaccines

The Vaccines and Related Biological Products Advisory Committee on May 28 approved the composition of COVID-19 vaccines for the 2026-2027 immunization season.

May 29, 2026

Vol.52 No.21

By Claire Marie Porter

Cancer Policy

HHS rescinds vaccine panel charter citing “administrative error”

The charter governing the Advisory Committee on Immunization Practices will be returned to its previous framework for two years because the Department of Health and Human Services didn’t allow sufficient time for public comment after Robert F. Kennedy crafted a charter more favorable to his policy preferences.

May 22, 2026

Vol.52 No.20

By Claire Marie Porter

Clinical Roundup

Intismeran cancer vaccine + Keytruda sustains 49% melanoma reduction after five years

A combination of a cancer vaccine and a drug, both of which harness the immune system to attack cancer cells, has proven successful in cutting the risk of skin cancer recurrence and death by 49%, according to a study led by researchers at NYU Langone Health and its Perlmutter Cancer Center.

May 22, 2026

Vol.52 No.20

Cancer Policy

CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, or ACIP, voted in December to rescind its recommendation that all newborns receive a hepatitis B virus vaccine dose within 24 hours of birth.

May 01, 2026

Vol.52 No.17

By Claire Marie Porter

YOU MAY BE INTERESTED IN

FDA advisory panel recommends first-of-its-kind mRNA flu vaccine for older adults

At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer

FDA advisory panel votes to recommend updated 2026-2027 formula for COVID-19 vaccines

HHS rescinds vaccine panel charter citing “administrative error”

Intismeran cancer vaccine + Keytruda sustains 49% melanoma reduction after five years

CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show

Renew today!

Subscriber content

Never miss an issue!

Login